The Autoimmune Attack May Start Years Before Diagnosis

Type 1 diabetes doesn't appear overnight. It develops through distinct stages, beginning with an autoimmune attack on the insulin-producing beta cells in the pancreas. This process starts with genetic predisposition—inherited risk factors—combined with an environmental trigger that sets the immune system against these cells.

What makes Type 1 diabetes complex is that this autoimmune attack can begin at almost any point in life: infancy, childhood, adolescence, or adulthood. Yet scientists still don't fully understand why the process starts early in some people and much later in others.

Many people diagnosed with Type 1 diabetes as adults may have had autoimmune activity underway for years without realizing it. The challenge is that without antibody screening, doctors and patients often don't know when the attack actually started.

Someone might develop symptoms and receive a Type 1 diabetes diagnosis in their 30s or 40s, but the autoimmune process could have begun decades earlier. Without early detection tools, there's no way to know whether the attack began recently or had been progressing silently for years.

Researchers now recognize Type 1 diabetes as having a presymptomatic phase—a period when autoimmune activity is happening but the person doesn't yet need insulin. This phase is divided into three stages:

Stage 1 occurs when autoantibodies are present but blood sugar remains normal. Stage 2 involves autoantibodies and abnormal blood sugar (dysglycemia). Stage 3 is marked by high blood sugar (hyperglycemia) and typically when people receive a clinical diagnosis and start insulin therapy.

This framework matters because it creates a window of opportunity. Identifying people in Stages 1 or 2—before they need insulin—opens the door to potential interventions that could delay or prevent progression to clinical disease.

The approval of teplizumab, a therapy that delays the onset of clinical Type 1 diabetes, has made early identification urgent. To use such therapies effectively, doctors need to identify people who are in the early stages of autoimmunity—before symptoms appear.

This is challenging because fewer than 1 in 200 individuals develop Type 1 diabetes. Still, screening for islet autoantibodies—the markers of autoimmune activity—can now identify people in these early stages. Researchers are also developing more convenient screening methods, including home-based glucose tolerance tests, to make detection more accessible.

As this field evolves, refining diagnostic approaches will be essential to ensure that screening accurately identifies those at risk and can be applied broadly to catch autoimmunity in its earliest stages.

Origin: YouTube / Emily King, MD (Video report). Evidence: Video report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.